Thompson Siegel & Walmsley LLC Sells 92,502 Shares of Perrigo Company plc (NYSE:PRGO)

Thompson Siegel & Walmsley LLC lowered its holdings in Perrigo Company plc (NYSE:PRGO - Free Report) by 2.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,057,819 shares of the company's stock after selling 92,502 shares during the period. Perrigo comprises 1.2% of Thompson Siegel & Walmsley LLC's holdings, making the stock its 17th largest position. Thompson Siegel & Walmsley LLC owned approximately 2.24% of Perrigo worth $80,207,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in Perrigo by 3.6% in the second quarter. Dimensional Fund Advisors LP now owns 7,162,656 shares of the company's stock valued at $183,935,000 after purchasing an additional 249,640 shares during the last quarter. Deprince Race & Zollo Inc. increased its holdings in Perrigo by 11.2% in the 2nd quarter. Deprince Race & Zollo Inc. now owns 3,882,438 shares of the company's stock worth $99,701,000 after acquiring an additional 391,646 shares during the last quarter. Cooke & Bieler LP raised its stake in Perrigo by 0.9% in the 2nd quarter. Cooke & Bieler LP now owns 3,501,401 shares of the company's stock valued at $89,916,000 after acquiring an additional 30,150 shares during the period. Copeland Capital Management LLC lifted its holdings in Perrigo by 23.1% during the third quarter. Copeland Capital Management LLC now owns 2,482,544 shares of the company's stock valued at $65,117,000 after purchasing an additional 465,161 shares during the last quarter. Finally, Sound Shore Management Inc. CT boosted its position in Perrigo by 5.2% during the second quarter. Sound Shore Management Inc. CT now owns 2,391,049 shares of the company's stock worth $61,402,000 after purchasing an additional 117,230 shares during the period. Institutional investors own 95.91% of the company's stock.

Perrigo Price Performance

NYSE:PRGO traded down $0.07 during trading hours on Thursday, hitting $27.08. The stock had a trading volume of 1,289,204 shares, compared to its average volume of 1,625,273. The firm has a market capitalization of $3.69 billion, a price-to-earnings ratio of -23.02 and a beta of 0.48. Perrigo Company plc has a one year low of $23.89 and a one year high of $34.60. The company has a 50 day simple moving average of $25.98 and a two-hundred day simple moving average of $27.17. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.56 and a quick ratio of 1.77.

Perrigo (NYSE:PRGO - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.81 EPS for the quarter, hitting the consensus estimate of $0.81. The business had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.12 billion. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The firm's revenue was down 3.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.64 earnings per share. Research analysts forecast that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 17th. Shareholders of record on Friday, November 29th will be paid a $0.276 dividend. The ex-dividend date is Friday, November 29th. This represents a $1.10 dividend on an annualized basis and a yield of 4.08%. Perrigo's dividend payout ratio is presently -94.02%.

Analyst Ratings Changes

PRGO has been the topic of a number of recent research reports. StockNews.com upgraded shares of Perrigo from a "hold" rating to a "buy" rating in a research note on Thursday, November 7th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $42.00 price target on shares of Perrigo in a report on Monday, September 30th. Finally, Jefferies Financial Group reiterated a "hold" rating and set a $30.00 price objective (down from $50.00) on shares of Perrigo in a research note on Monday, September 23rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.00.

Insider Transactions at Perrigo

In related news, EVP Ronald Craig Janish sold 13,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $29.40, for a total transaction of $382,200.00. Following the transaction, the executive vice president now owns 20,553 shares of the company's stock, valued at approximately $604,258.20. This trade represents a 38.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Katherine C. Doyle sold 8,954 shares of the business's stock in a transaction on Friday, September 13th. The stock was sold at an average price of $27.30, for a total transaction of $244,444.20. Following the completion of the sale, the director now directly owns 6,009 shares of the company's stock, valued at $164,045.70. This represents a 59.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.70% of the company's stock.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.